Download MendeleyStructural basis for the inhibition of coronaviral main proteases by ensitrelvir.
Lin, C., Jiang, H., Li, W., Zeng, P., Zhou, X., Zhang, J., Li, J.(2023) Structure 31: 1016-1024.e3
- PubMed: 37421945
- DOI: https://doi.org/10.1016/j.str.2023.06.010
- Primary Citation of Related Structures:
8HUR, 8HUS, 8HUT, 8HUU, 8HUV, 8HUW, 8HUX - PubMed Abstract:
Main protease (M pro ) is a highly conserved cysteine protease that plays a vital role in the replication of coronaviruses, making it an attractive pan-coronaviral therapeutic target. Ensitrelvir (S-217622), developed by Shionogi, is the first orally active non-covalent, non-peptidic SARS-CoV-2 M pro inhibitor, which also displays antiviral efficacy against other human coronaviruses as well as SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs). Here, we report the crystal structures of the main proteases from SARS-CoV-2, SARS-CoV-2 VOC/VOIs, SARS-CoV, MERS-CoV, and HCoV-NL63 bound to the inhibitor S-217622. A detailed analysis of these structures illuminates key structural determinants essential for inhibition and elucidates the binding modes of the main proteases from different coronaviruses. Given the importance of the main protease for the treatment of coronaviral infection, structural insights obtained from this study could accelerate the design of novel antivirals with broad-spectrum efficacy against different human coronaviruses.
Organizational Affiliation:
College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
